## Pacylex Pharmaceuticals

Edmonton, Alberta, Canada

Pacylex Pharmaceuticals is an oncology company unlocking a new approach to cancer therapy using a first-in-class, small molecule, N-myristoyltransferase (NMT) inhibitor, PCLX-001, targeting the biological process of myristoylation.

Pacylex was formed in 2012 to exploit insights from Dr. Luc Berthiaume and colleagues at the University of Alberta, connecting myristoylation to cancer creating a potential diagnostic approach. In 2015, a family of high quality myristoylation inhibitors was exclusively licensed from the University of Dundee extending the company's business into therapeutics. PCLX-001 is the lead drug in this new class of NMT inhibitors.

PCLX-001 was originally developed by the University of Dundee Drug Discovery Unit as part of a program funded by Wellcome Trust to treat African sleeping sickness. PCLX-001 has excellent oral bioavailability and selectively kills cancer cells and completely regresses (eliminates) tumors in animal models of acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), with lymphoma research published in 2020 in *Nature Communications*. PCLX-001 also inhibits the growth of lung and breast cancer tumors in animal models, with breast cancer results published in *Breast Cancer Research and Treatment* in 2021. In tests using cultured cancer cells *in vitro*, PCLX-001 is at least ten times as potent as ibrutinib (Imbruvica) and dasatinib (Sprycel), two clinically approved drugs currently used to treat hematologic malignancies.

A No Objection Letter from Health Canada was received by Pacylex on March 8, 2021, authorizing the planned Phase 1 Trial of PCLX-001 in patients with relapsed/refractory B-cell Non-Hodgkin Lymphoma and advanced solid malignancies. PCLX-001 is believed to be the first NMT inhibitor that will be clinically tested. Three principal investigators will oversee the clinical study at three clinical sites in Canada: Dr. John Kuruvilla at Princess Margaret Cancer Centre in Toronto, Dr. Randeep Sangha at the Cross Cancer Institute in Edmonton and Dr. Laurie Sehn at the British Columbia Cancer Center in Vancouver. Clinical site preparations are underway for the open label, dose escalation, Phase 1 clinical trial, principally to evaluate the safety of PCLX-001. The study will enroll 20-30 patients and the Company anticipates that enrollment will begin dosing in June or July 2021.

On June 2, 2021, Pacylex announced it had closed a Series A financing with Greenfire Bio, a new Life Science development and investment company. These funds will be used to support the initial Phase 1 clinical investigation of PCLX-001 in patients with relapsed/refractory B-cell Non-Hodgkin Lymphoma and advanced solid malignancies.

Pacylex is also receiving support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation.

**Contact:** Michael J. Weickert, PhD, CEO, Pacylex Pharmaceuticals
Tele: 650-218-1840
www.pacylex.com